Literature DB >> 29600036

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

Niels Steinebrunner1, Wolfgang Stremmel1, Karl H Weiss1.   

Abstract

Entities:  

Year:  2018        PMID： 29600036      PMCID： PMC5863157          DOI： 10.21037/jtd.2017.12.117

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

Review 1.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

Review 2.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

Review 3.  Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-10       Impact factor: 46.802

4.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

Authors:  Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

Review 5.  New and emerging therapies for Clostridium difficile infection.

Authors:  Jessica Martin; Mark Wilcox
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

Review 6.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

7.  Salmonella enterica serovar Minnesota urosepsis in a patient with Crohn's disease in the absence of recent or current gastrointestinal symptoms.

Authors:  Niels Steinebrunner; Catharina Sandig; Stefan Zimmermann; Wolfgang Stremmel; Christoph Eisenbach; Alexander Mischnik
Journal:  J Med Microbiol       Date:  2013-06-20       Impact factor: 2.472

8.  Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Authors:  Oliver A Cornely; Mark A Miller; Thomas J Louie; Derrick W Crook; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

9.  A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.

Authors:  Richard Vickers; Neil Robinson; Emma Best; Roger Echols; Glenn Tillotson; Mark Wilcox
Journal:  BMC Infect Dis       Date:  2015-02-25       Impact factor: 3.090

10.  Emergence and global spread of epidemic healthcare-associated Clostridium difficile.

Authors:  Miao He; Fabio Miyajima; Paul Roberts; Louise Ellison; Derek J Pickard; Melissa J Martin; Thomas R Connor; Simon R Harris; Derek Fairley; Kathleen B Bamford; Stephanie D'Arc; Jon Brazier; Derek Brown; John E Coia; Gill Douce; Dale Gerding; Hee Jung Kim; Tse Hsien Koh; Haru Kato; Mitsutoshi Senoh; Tom Louie; Stephen Michell; Emma Butt; Sharon J Peacock; Nick M Brown; Tom Riley; Glen Songer; Mark Wilcox; Munir Pirmohamed; Ed Kuijper; Peter Hawkey; Brendan W Wren; Gordon Dougan; Julian Parkhill; Trevor D Lawley
Journal:  Nat Genet       Date:  2012-12-09       Impact factor: 38.330
View more
  2 in total

1.  A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile.

Authors:  Rajani Thanissery; Daina Zeng; Raul G Doyle; Casey M Theriot
Journal:  Front Microbiol       Date:  2018-06-06       Impact factor: 5.640

Review 2.  Antibiotics in the pipeline: a literature review (2017-2020).

Authors:  Jaffar A Al-Tawfiq; Hisham Momattin; Anfal Y Al-Ali; Khalid Eljaaly; Raghavendra Tirupathi; Mohamed Bilal Haradwala; Swetha Areti; Saad Alhumaid; Ali A Rabaan; Abbas Al Mutair; Patricia Schlagenhauf
Journal:  Infection       Date:  2021-10-04       Impact factor: 3.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.